Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neuroimmunol. 2011 Apr;233(1-2):168-74. doi: 10.1016/j.jneuroim.2010.10.038. Epub 2010 Nov 27.

Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments.

Author information

  • 1Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.

Abstract

Using retrospectively collected outcome data for treatment naïve subjects treated with either glatiramer acetate (GA) (n=332) or interferon beta (IFN β) (n=424), we replicated the lack of a significant difference in efficacy between these treatments. Further, for both treatments, we observed a decline in the hazard of a relapse over time, which may suggest the existence of subsets of subjects with differential responses to each treatment. The HLA DRB1 1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN β treated subjects.

Copyright © 2010 Elsevier B.V. All rights reserved.

PMID:
21115201
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk